Lantheus Holdings Inc

Lantheus Holdings is a radiopharmaceutical-focused company that develops, manufactures and commercializes diagnostic imaging agents and targeted therapeutics. It frames its mission as helping clinicians 'Find, Fight and Follow' disease, and it has provided radiopharmaceutical solutions for 70 years.

Its commercial portfolio spans three areas:
- **Oncology**: PYLARIFY, an F-18 PSMA PET imaging agent for prostate cancer, and its new formulation PYLARIFY TruVu, approved by the FDA in March 2026 and now in a phased launch.
- **Neurology**: Neuraceq, an amyloid PET imaging agent.
- **Cardiology**: DEFINITY, an ultrasound enhancing agent.

The company also earns revenue from strategic partnerships, including its Pharma Solutions business, which supplies imaging agents to support Alzheimer's therapeutic programs. Recent FDA approvals include TAUKLARIFY (florquinitau F-18), a tau PET agent, and BRAVNETSA (lutetium Lu 177 dotatate), a therapeutic equivalent to LUTATHERA for GEP-NETs.

The pipeline includes:
- LNTH-2401, a GRPR-targeted prostate cancer PET agent in the Phase 2/3 SPARROW trial.
- LNTH-2501, a Ga-68 edotreotide kit that received a Complete Response Letter in June 2026.
- NAV-4694.

The company has divested its SPECT business and is focusing mainly on radiodiagnostics while pursuing value-maximizing alternatives for its radiotherapeutic assets. Lantheus has agreed to be acquired by Curium in an all-cash deal worth up to approximately $8.0 billion including CVRs. Updated Nov 5, 2026